The effect of steroid pretreatment of deceased organ donors on liver allograft function

A blinded randomized placebo-controlled trial

Stefan Amatschek, Julia Wilflingseder, Mario Pones, Alexander Kainz, Martin Bodingbauer, Ferdinand Mühlbacher, R. Langer, Zsuzsanna Gerlei, Rainer Oberbauer

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background & Aims: Brain death-associated inflammatory response contributes to increased risk of impaired early liver allograft function, which might be counterbalanced by steroid pretreatment of the organ donor. The aim of this randomized controlled trial was to elucidate whether steroid pretreatment of liver donors improves early liver allograft function, prevents rejection and prolongs survival. Methods: A placebo-controlled blinded randomized clinical trial was performed in three different centers in Austria and Hungary between 2006 and 2008. Ninety deceased organ donors received either 1000 mg of methylprednisolone or placebo 6 h before recovery of organs. The primary end point was the concentration slope of transaminases within the first week. The secondary end point included survival and biopsy-confirmed acute rejection (BCAR) within 3 years after transplantation. Results: Of the 90 randomized donors, 83 recipients were eligible for study. The trajectories of ALT and AST were not different between treatments (p = 0.40 and p = 0.13, respectively). Eight subjects died in the steroid and 13 in the placebo group within 3 years after engraftment (RR = 0.63 95% CI [0.29, 1.36], p = 0.31). Eleven recipients experienced biopsy-confirmed rejection (BCAR) in the steroid and 11 in the placebo group (RR = 1.02 95% CI [0.50, 2.10], p = 1.00). No effect modification could be identified in the predefined strata of donor age, sex, cold ischemic time, and cause of donor death. Conclusions: Steroid pretreatment of organ donors did not improve outcomes after liver transplantation.

Original languageEnglish
Pages (from-to)1305-1309
Number of pages5
JournalJournal of Hepatology
Volume56
Issue number6
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Allografts
Randomized Controlled Trials
Steroids
Placebos
Tissue Donors
Liver
Biopsy
Austria-Hungary
Cold Ischemia
Brain Death
Survival
Methylprednisolone
Transaminases
Liver Transplantation
Cause of Death
Transplantation

Keywords

  • Donor pretreatment
  • Early liver allograft function
  • Liver transplantation
  • Steroid

ASJC Scopus subject areas

  • Hepatology

Cite this

Amatschek, S., Wilflingseder, J., Pones, M., Kainz, A., Bodingbauer, M., Mühlbacher, F., ... Oberbauer, R. (2012). The effect of steroid pretreatment of deceased organ donors on liver allograft function: A blinded randomized placebo-controlled trial. Journal of Hepatology, 56(6), 1305-1309. https://doi.org/10.1016/j.jhep.2012.01.020

The effect of steroid pretreatment of deceased organ donors on liver allograft function : A blinded randomized placebo-controlled trial. / Amatschek, Stefan; Wilflingseder, Julia; Pones, Mario; Kainz, Alexander; Bodingbauer, Martin; Mühlbacher, Ferdinand; Langer, R.; Gerlei, Zsuzsanna; Oberbauer, Rainer.

In: Journal of Hepatology, Vol. 56, No. 6, 06.2012, p. 1305-1309.

Research output: Contribution to journalArticle

Amatschek, S, Wilflingseder, J, Pones, M, Kainz, A, Bodingbauer, M, Mühlbacher, F, Langer, R, Gerlei, Z & Oberbauer, R 2012, 'The effect of steroid pretreatment of deceased organ donors on liver allograft function: A blinded randomized placebo-controlled trial', Journal of Hepatology, vol. 56, no. 6, pp. 1305-1309. https://doi.org/10.1016/j.jhep.2012.01.020
Amatschek, Stefan ; Wilflingseder, Julia ; Pones, Mario ; Kainz, Alexander ; Bodingbauer, Martin ; Mühlbacher, Ferdinand ; Langer, R. ; Gerlei, Zsuzsanna ; Oberbauer, Rainer. / The effect of steroid pretreatment of deceased organ donors on liver allograft function : A blinded randomized placebo-controlled trial. In: Journal of Hepatology. 2012 ; Vol. 56, No. 6. pp. 1305-1309.
@article{5ee01fb1a1374570b037d654d864496f,
title = "The effect of steroid pretreatment of deceased organ donors on liver allograft function: A blinded randomized placebo-controlled trial",
abstract = "Background & Aims: Brain death-associated inflammatory response contributes to increased risk of impaired early liver allograft function, which might be counterbalanced by steroid pretreatment of the organ donor. The aim of this randomized controlled trial was to elucidate whether steroid pretreatment of liver donors improves early liver allograft function, prevents rejection and prolongs survival. Methods: A placebo-controlled blinded randomized clinical trial was performed in three different centers in Austria and Hungary between 2006 and 2008. Ninety deceased organ donors received either 1000 mg of methylprednisolone or placebo 6 h before recovery of organs. The primary end point was the concentration slope of transaminases within the first week. The secondary end point included survival and biopsy-confirmed acute rejection (BCAR) within 3 years after transplantation. Results: Of the 90 randomized donors, 83 recipients were eligible for study. The trajectories of ALT and AST were not different between treatments (p = 0.40 and p = 0.13, respectively). Eight subjects died in the steroid and 13 in the placebo group within 3 years after engraftment (RR = 0.63 95{\%} CI [0.29, 1.36], p = 0.31). Eleven recipients experienced biopsy-confirmed rejection (BCAR) in the steroid and 11 in the placebo group (RR = 1.02 95{\%} CI [0.50, 2.10], p = 1.00). No effect modification could be identified in the predefined strata of donor age, sex, cold ischemic time, and cause of donor death. Conclusions: Steroid pretreatment of organ donors did not improve outcomes after liver transplantation.",
keywords = "Donor pretreatment, Early liver allograft function, Liver transplantation, Steroid",
author = "Stefan Amatschek and Julia Wilflingseder and Mario Pones and Alexander Kainz and Martin Bodingbauer and Ferdinand M{\"u}hlbacher and R. Langer and Zsuzsanna Gerlei and Rainer Oberbauer",
year = "2012",
month = "6",
doi = "10.1016/j.jhep.2012.01.020",
language = "English",
volume = "56",
pages = "1305--1309",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - The effect of steroid pretreatment of deceased organ donors on liver allograft function

T2 - A blinded randomized placebo-controlled trial

AU - Amatschek, Stefan

AU - Wilflingseder, Julia

AU - Pones, Mario

AU - Kainz, Alexander

AU - Bodingbauer, Martin

AU - Mühlbacher, Ferdinand

AU - Langer, R.

AU - Gerlei, Zsuzsanna

AU - Oberbauer, Rainer

PY - 2012/6

Y1 - 2012/6

N2 - Background & Aims: Brain death-associated inflammatory response contributes to increased risk of impaired early liver allograft function, which might be counterbalanced by steroid pretreatment of the organ donor. The aim of this randomized controlled trial was to elucidate whether steroid pretreatment of liver donors improves early liver allograft function, prevents rejection and prolongs survival. Methods: A placebo-controlled blinded randomized clinical trial was performed in three different centers in Austria and Hungary between 2006 and 2008. Ninety deceased organ donors received either 1000 mg of methylprednisolone or placebo 6 h before recovery of organs. The primary end point was the concentration slope of transaminases within the first week. The secondary end point included survival and biopsy-confirmed acute rejection (BCAR) within 3 years after transplantation. Results: Of the 90 randomized donors, 83 recipients were eligible for study. The trajectories of ALT and AST were not different between treatments (p = 0.40 and p = 0.13, respectively). Eight subjects died in the steroid and 13 in the placebo group within 3 years after engraftment (RR = 0.63 95% CI [0.29, 1.36], p = 0.31). Eleven recipients experienced biopsy-confirmed rejection (BCAR) in the steroid and 11 in the placebo group (RR = 1.02 95% CI [0.50, 2.10], p = 1.00). No effect modification could be identified in the predefined strata of donor age, sex, cold ischemic time, and cause of donor death. Conclusions: Steroid pretreatment of organ donors did not improve outcomes after liver transplantation.

AB - Background & Aims: Brain death-associated inflammatory response contributes to increased risk of impaired early liver allograft function, which might be counterbalanced by steroid pretreatment of the organ donor. The aim of this randomized controlled trial was to elucidate whether steroid pretreatment of liver donors improves early liver allograft function, prevents rejection and prolongs survival. Methods: A placebo-controlled blinded randomized clinical trial was performed in three different centers in Austria and Hungary between 2006 and 2008. Ninety deceased organ donors received either 1000 mg of methylprednisolone or placebo 6 h before recovery of organs. The primary end point was the concentration slope of transaminases within the first week. The secondary end point included survival and biopsy-confirmed acute rejection (BCAR) within 3 years after transplantation. Results: Of the 90 randomized donors, 83 recipients were eligible for study. The trajectories of ALT and AST were not different between treatments (p = 0.40 and p = 0.13, respectively). Eight subjects died in the steroid and 13 in the placebo group within 3 years after engraftment (RR = 0.63 95% CI [0.29, 1.36], p = 0.31). Eleven recipients experienced biopsy-confirmed rejection (BCAR) in the steroid and 11 in the placebo group (RR = 1.02 95% CI [0.50, 2.10], p = 1.00). No effect modification could be identified in the predefined strata of donor age, sex, cold ischemic time, and cause of donor death. Conclusions: Steroid pretreatment of organ donors did not improve outcomes after liver transplantation.

KW - Donor pretreatment

KW - Early liver allograft function

KW - Liver transplantation

KW - Steroid

UR - http://www.scopus.com/inward/record.url?scp=84861202973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861202973&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2012.01.020

DO - 10.1016/j.jhep.2012.01.020

M3 - Article

VL - 56

SP - 1305

EP - 1309

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 6

ER -